Global burden of metabolic dysfunction-associated steatotic liver disease, 1990-2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023 - PubMed
4 hours ago
- #Global Burden of Disease
- #MASLD
- #Liver Disease
- In 2023, approximately 1.3 billion people (16.1% of global population) were living with MASLD, a 142.7% increase in crude cases since 1990.
- Age-standardized prevalence was higher in males than females and peaked at age 80-84 years, while total cases peaked in younger adults (35-39 for males, 55-59 for females).
- North Africa and the Middle East had the highest prevalence rate, whereas high-income Asia Pacific had the lowest.
- MASLD contributed to 3.6 million DALYs globally in 2023, with the highest age-standardized DALY rate in Andean Latin America and the lowest in East Asia.
- High fasting plasma glucose was the leading risk factor for MASLD DALYs, followed by high BMI and smoking.
- Projections estimate 1.8 billion people will have MASLD by 2050, a 42% increase from 2023, driven primarily by population growth, especially in sub-Saharan Africa and North Africa/Middle East.
- Lower Healthcare Access and Quality Index scores were associated with higher DALY rates, highlighting health system challenges in managing MASLD burden.